Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

As the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B. 1.1. 529)
has quickly become the dominant type among the previous circulating variants worldwide …

Abstract In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified,
and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that …

In late 2022, various Omicron subvariants emerged and cocirculated worldwide. These
variants convergently acquired amino acid substitutions at critical residues in the spike …

Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly
protective vaccines against novel pandemic coronaviruses and to more effectively respond …

Summary BA. 2.86, a recently identified descendant of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) Omicron BA. 2 sublineage, contains∼ 35 mutations …

Since late 2022, the share of infections caused by the SARS-CoV-2 lineage XBB. 1.5 has
gradually increased in the United States, resulting in XBB. 1.5 becoming the dominating …

Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has …

The ongoing global pandemic of coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused devastating impacts …

Background Outpatient monoclonal antibodies are no longer effective and antiviral
treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in …